Table 1.
Summary of studies included in meta-analysis of trials of fluticasone in adults and adolescents with asthma
| Study | No of patients | Duration of study (weeks) | Doses of FP (μg/day) | Device | Range (mean) of FEV1 as % of predicted | Age (mean) | Baseline ICS usage | Outcomes measured
|
|||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FEV1 | Morning PEF | Evening PEF | β agonist use | Exacerbations | Night awakenings | ||||||||
| Chervinsky5 | 331 | 8 | 50; 200; 1000 | MDI | 60-90 (72) | ⩾18 (38) | 8-16 puffs BDP/ day | √ | √ | √ | √ | — | √ |
| Sheffer6 | 307 | 12 | 50; 100; 200 | MDI | 45-75 (63) | ⩾12 (30) | 0 | √ | √ | √ | √ | √ | — |
| Galant7 | 353 | 12 | 100; 200 | MDI | 45-75 (61) | 12-75 (30) | ⩾0 | √ | √ | — | √ | √ | √ |
| Wolfe8 | 281 | 12 | 200; 500; 1000 | MDI | (65) | 12-87 (34) | >0 | √ | √ | — | √ | √ | √ |
| Lawrence9 | 261 | 6 | 200; 1000 | Diskhaler | 50-80 (66) | ⩾18 | >0 | √ | √ | — | √ | √ | √ |
| Wasserman10 | 321 | 12 | 100; 200; 800 | Diskhaler | 50-80 | ⩾12 | ⩾0 | √ | √ | √ | √ | √ | √ |
| Noonan11 | 105 | 8 | 100; 200 | MDI | 60-85 (74) | 12-57 (28) | 0 | √ | √ | √ | √ | √ | √ |
| Pearlman12 | 342 | 12 | 100; 200; 800 | Diskhaler | 50-80 (67) | 12-72 (35) | >0 | √ | √ | √ | √ | √ | √ |
FP=fluticasone propionate; FEV1=forced expiratory volume in one second; ICS=inhaled corticosteroid; PEF=peak expiratory flow; MDI=metered dose inhaler; BDP=beclometasone dipropionate.